Spermidine May Reverse Liver Fibrosis by Disrupting Cell Communication

A 2026 study published in Cell Death Discovery reveals how spermidine could help reverse liver fibrosis. The research highlights its ability to disrupt harmful communication between liver cells, offering a new approach to treatment. Current therapies often focus on single cell types, but this work shows broader potential by targeting cell interactions. Liver fibrosis develops when hepatic stellate cells (HSCs) produce too much collagen and extracellular matrix, often triggered by signals from liver sinusoidal endothelial cells (LSECs). Over time, this leads to scarring, cirrhosis, and liver failure. The study examined how spermidine interferes with these processes.

Researchers used advanced in vitro co-culture systems and animal models to track spermidine’s effects. They found it suppresses fibrosis by blocking key pathways in HSCs. Specifically, it reduces TGF-β receptor levels and Smad phosphorylation, stopping the cells from turning into collagen-producing myofibroblasts.

Spermidine also boosts nitric oxide (NO) production in LSECs, improving blood vessel function. This weakens the signals that activate HSCs, breaking the cycle of scarring. Additionally, the compound alters epigenetic markers, promoting long-term antifibrotic gene activity in both cell types.

The findings suggest spermidine’s dual action—restoring endothelial health and quieting stellate cells—could be more effective than targeting one cell type alone. The study confirms spermidine’s potential as a fibrosis treatment by reshaping cell communication and gene expression. Its ability to reverse pathological liver changes in models points to future clinical applications. Researchers now emphasise the need to explore therapies that address intercellular interactions rather than isolated mechanisms.